BioMarin Pharmaceutical downgraded by Stifel with a new price target
$BMRN
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel downgraded BioMarin Pharmaceutical from Buy to Hold and set a new price target of $61.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/3/2025 | $60.00 | Outperform → Market Perform | Leerink Partners |
| 11/6/2025 | $61.00 | Buy → Hold | Stifel |
| 9/8/2025 | $60.00 | Neutral | H.C. Wainwright |
| 9/3/2025 | $85.00 | Outperform | Raymond James |
| 7/3/2025 | $97.00 | Overweight | Morgan Stanley |
| 2/24/2025 | $98.00 | Perform → Outperform | Oppenheimer |
| 11/15/2024 | $95.00 | Outperform | Wolfe Research |
| 10/30/2024 | Outperform → Mkt Perform | William Blair |
8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
8-K - BIOMARIN PHARMACEUTICAL INC (0001048477) (Filer)
SAN RAFAEL, Calif., Jan. 8, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will present at the 44th Annual J.P. Morgan Conference on Monday, January 12, 2026, at 11:15 am PT / 2:15 pm ET, in San Francisco, California. The Company plans to announce certain preliminary financial results for the year ended December 31, 2025 at such event. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived
Partnership to help BioMarin increase speed and efficiency in developing and commercializing innovative therapies PLEASANTON, Calif., and SAN RAFAEL, Calif., Jan. 8, 2026 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced a long-term enterprise agreement that builds upon their long-standing relationship. The expanded partnership will help BioMarin increase speed, agility, operational efficiency, and optimize the healthcare professional and patient experience by further leveraging and providing strategic input into Veeva's softwar
BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Million in Revenue Over Past Four Quarters Provides Opportunity to Expand Access to Galafold and Pombiliti + Opfolda to Patients in New Markets Across BioMarin's Global Footprint; Pending U.S. Galafold Patent Litigation Resolved Will Accelerate Revenue Growth Immediately After Close; Expected to be Accretive to Non-GAAP Diluted Earnings Per Share (EPS) in the First 12 Months Post-Close and Substantially Accretive to Non-GAAP Diluted EPS Beginning in 2027 Conference Call Today at 8:15 a.m. Eastern Tim
For Immediate Release: June 29, 2023 Today, the U.S. Food and Drug Administration approved Roctavian, an adeno-associated virus vector-based gene therapy for the treatment of adults with severe hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test. “Hereditary hemophilia A is a potentially serious bleeding disorder. Severe cases of hemophilia A can ca
Leerink Partners downgraded BioMarin Pharmaceutical from Outperform to Market Perform and set a new price target of $60.00
Stifel downgraded BioMarin Pharmaceutical from Buy to Hold and set a new price target of $61.00
H.C. Wainwright initiated coverage of BioMarin Pharmaceutical with a rating of Neutral and set a new price target of $60.00
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
4 - BIOMARIN PHARMACEUTICAL INC (0001048477) (Issuer)
SAN RAFAEL, Calif., Aug. 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that the company has appointed Ian T. Clark to the company's Board of Directors, effective today, August 1, 2025. Mr. Clark served as Chief Executive Officer of Genentech and a member of the company's Board of Directors from 2010 until his retirement in 2016. Under his leadership, Genentech launched 15 new drugs. Prior to serving as CEO, Mr. Clark held a number of senior management positions at Genentech. Before joining Genentech, Mr. Clark spent 23 years in the biopharmaceuti
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of
BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Million in Revenue Over Past Four Quarters Provides Opportunity to Expand Access to Galafold and Pombiliti + Opfolda to Patients in New Markets Across BioMarin's Global Footprint; Pending U.S. Galafold Patent Litigation Resolved Will Accelerate Revenue Growth Immediately After Close; Expected to be Accretive to Non-GAAP Diluted Earnings Per Share (EPS) in the First 12 Months Post-Close and Substantially Accretive to Non-GAAP Diluted EPS Beginning in 2027 Conference Call Today at 8:15 a.m. Eastern Tim
Raises Full-year 2025 Total Revenues Guidance at the Midpoint; Reaffirms VOXZOGO Full-year Outlook 2025 Year-to-date Total Revenues Increased 11% Y/Y Led by More Than 20% Revenue Growth for PALYNZIQ and VOXZOGO BioMarin Focuses Commercial Portfolio; Pursuing Options to Divest ROCTAVIAN Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., Oct. 27, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced financial results for the third quarter ended September 30, 2025. "We are pleased with the contributions from our Enzyme Therap
SAN RAFAEL, Calif., Oct. 22, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, October 27, 2025, at 4:30 p.m. ET to discuss third quarter 2025 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 800-715-9871International Dial-in Number: 646-307-1963Conference Call ID: 4998437 U.S. / Canada Replay Dial-in Number: 800-770-2030International Replay Dial-in Number: 609-800-9909Pla
SC 13G - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)
SC 13G/A - BIOMARIN PHARMACEUTICAL INC (0001048477) (Subject)